Background. Insulin resistance is a common risk factor in chronic kidney disease patients contributing to the high cardiovascular burden, even in the absence of diabetes. Glucose-based peritoneal dialysis (PD) solutions are thought to intensify insulin resistance due to the continuous glucose absorption from the peritoneal cavity. The aim of our study was to analyse the effect of the substitution of glucose for icodextrin on insulin resistance in non-diabetic PD patients in a multicentric randomized clinical trial. Methods. This was a multicenter, open-label study with balanced randomization (1:1) and two parallel-groups. Inclusion criteria were non-diabetic adult patients on automated peritoneal dialysis (APD) for at least 3 months on therapy prior to randomization. Patients assigned to the intervention group were treated with 2L of icodextrin 7.5%, and the control group with glucose 2.5% during the long dwell and, at night in the cycler, with a prescription of standard glucose-based PD solution only in both groups. The primary end-point was the change in insulin resistance measured by homeostatic model assessment (HOMA) index at 90 days. Results. Sixty patients were included in the intervention (n = 33) or the control (n = 27) groups. There was no difference between groups at baseline. After adjustment for pre-intervention HOMA index levels, the group treated with icodextrin had
A B S T R AC T
Background. Insulin resistance is a common risk factor in chronic kidney disease patients contributing to the high cardiovascular burden, even in the absence of diabetes. Glucose-based peritoneal dialysis (PD) solutions are thought to intensify insulin resistance due to the continuous glucose absorption from the peritoneal cavity. The aim of our study was to analyse the effect of the substitution of glucose for icodextrin on insulin resistance in non-diabetic PD patients in a multicentric randomized clinical trial. Methods. This was a multicenter, open-label study with balanced randomization (1:1) and two parallel-groups. Inclusion criteria were non-diabetic adult patients on automated peritoneal dialysis (APD) for at least 3 months on therapy prior to randomization. Patients assigned to the intervention group were treated with 2L of icodextrin 7.5%, and the control group with glucose 2.5% during the long dwell and, at night in the cycler, with a prescription of standard glucose-based PD solution only in both groups. The primary end-point was the change in insulin resistance measured by homeostatic model assessment (HOMA) index at 90 days. Results. Sixty patients were included in the intervention (n = 33) or the control (n = 27) groups. There was no difference between groups at baseline. After adjustment for pre-intervention HOMA index levels, the group treated with icodextrin had the lower post-intervention levels at 90 days in both intention to treat [1. 49 (95% CI: 1.23-1.74) versus 1.89 (95% CI: 1.62-2.17)], (F = 4.643, P = 0.03, partial η 2 = 0.078); and the treated analysis [1.47 (95% CI: 1.01-1.84) versus 2.18 (95% CI: 1.81-2.55)], (F = 7.488, P = 0.01, partial η 2 = 0.195). Conclusions. The substitution of glucose for icodextrin for the long dwell improved insulin resistance measured by HOMA index in non-diabetic APD patients.
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I N T R O D U C T I O N
Peritoneal dialysis (PD) patients are exposed to a high cardiovascular disease (CVD) burden. In addition to the high prevalence of risk factors for CVD, such as older age, diabetes, dyslipidemia and hypertension, other factors related to chronic kidney disease (CKD) as the accumulation of uremic toxins, inflammation, anemia, volume overload, mineral metabolism disorders and, particularly in PD, disorders of the glucose homeostasis due to a high glucose load may amplify the risk [1, 2] .
Glucose is the most common osmotic agent used in PD solutions to generate adequate ultrafiltration (UF). After the initiation of PD, partial correction of uremia improves insulin resistance, although not to normal levels [3] . On the other hand, glucose-based PD prescriptions clearly increase the risk of hyperglycemia, worsening of insulin resistance and development of new-onset diabetes and a status of insulin resistance due to the high glucose load that characterizes PD treatment with standard glucose-based solutions [4, 5] . The substitution of traditional glucose-based PD solutions by glucose-sparing agents is an interesting approach to reduce the exposure to high glucose load, improving the metabolic profile of PD patients [4] .
Icodextrin is a well-established colloid osmotic agent derived from starch that was developed in the 1990s, with the main goal of improving UF. There are several studies showing the beneficial effects of icodextrin in terms of UF [6] . Interestingly, the evidence of its benefit on glucose metabolism is still lacking, particularly in non-diabetic patients. There are only two randomized clinical trials using glucose metabolism as end points published until now: both performed in diabetic patients, whereas one study [7] included only high transporter continuous ambulatory peritoneal dialysis (CAPD) patients; the other is a multinational combination of two studies (IMPENDIA and EDEN) [8] ; both used changes in glycated hemoglobin (HbA1C) as a primary end point and observed a similar significant reduction in the levels of HbA1C at the end of follow-up.
Insulin resistance is a surrogate marker of the carbohydrate metabolism disorders and was previously associated with cardiovascular mortality in non-diabetic end-stage CKD patients [9] . Moreover, Canbakan et al. in a single-center, nonrandomized study including prevalent non-diabetic CAPD patients reported that the use of icodextrin in the long-dwell exchanges is associated with reduced insulin resistance as well as fewer metabolic and cardiovascular complications [10] . Nevertheless, no randomized clinical trial has ever assessed the impact of icodextrin on insulin resistance as the primary end point in non-diabetic APD patients.
Thus, the aim of our multicenter randomized clinical trial was to analyze the impact of the substitution of glucose 2.5% for icodextrin 7.5% as PD solution used for the long dwell on insulin resistance measured by homeostatic model assessment (HOMA) index as well as other markers of glucose homeostasis in non-diabetic patients treated with automated peritoneal dialysis (APD).
M E T H O D S
Trial design This is a Phase IV, open-label study with balanced randomization (1:1) and with two parallel-groups conducted in multiple Brazilian centers and coordinated at the Pontifícia Universidade Católica do Paraná. Patients were randomly assigned to the intervention group (icodextrin) or the control group (glucose) using a centralized randomization schedule implemented in the coordinating center and using the Random Allocation Software ® version 2.0. Randomization was stratified by study center.
Sample size calculation Sample size calculation was based on the assumption that to detect a reduction in HOMA index of 25% with a two-sided 5% significance level and a power of 80%, 60 patients were needed to be included in each arm, given an anticipated dropout rate of 30%. Most of the assumptions were based on very distinct populations and study designs. Therefore, the steering committee defined a priori that an interim analysis needed to be scheduled after the recruitment of 50% of the patients to re-assess the power calculation and avoid futility and unnecessary patient exposure to risk. The study was registered in clinicaltrials.gov under the number NCT01021878.
Participants
Adult non-diabetic patients on treatment with APD for at least 90 days and with a recent peritoneal equilibration test (PET) showing a D/P creatinine of >0.50 (low-average, high-average or high transporter) were included in the study. Exclusion criteria included not willing to participate in the study, a Charlson Index of >7 or a life expectancy of <1 year at baseline, a positive HIV serology, a peritonitis episode preceding the randomization by 1 month, any hospitalization due to cardiovascular, metabolic or infectious disease in the month preceding randomization, any known active cancer, pregnancy, known allergy to starch and a total Kt/V of <1.7 following the initial change in the prescription.
Setting
The study took place at seven distinct Brazilian PD centers distributed in five states or three regions (Northeast, Southeast and South) from October 2009 to February 2013. All patients were required to provide informed consent after detailed explanation of the study and before any activity related to the protocol. Ethical approval was obtained from all local ethics and research boards.
Interventions
Patients assigned to the intervention group were treated with 2 L of icodextrin 7.5% whereas the patients in the control group were treated with 2 L of glucose 2.5% during the long dwell. The total volume and the glucose concentration for the night APD prescription in both groups were defined locally, by each investigator, according to the patient's individual needs in terms of UF and clinical adequacy. Dry periods were not allowed, not even during the day scheduled for collection of blood and dialysate samples. Blood samples were collected with 10 h of oral fasting, and at a maximum of 3 h, but not less than 1 h-30 min, after the patient was disconnected from the cycler. Oral fasting was ascertained by questioning the patient before blood sample collection on the day of the scheduled study visit. The peritoneal cavity was infused with the PD solution prescribed for the long dwell. All biochemical analyses were performed at a central laboratory (Diagnósticos do Brasil ® , Curitiba, Brazil).
Outcomes
The primary outcome was the change in insulin resistance measured by HOMA index from baseline to 3 months. HOMA index has been validated by previous studies. It presents a very good correlation with the euglycemic clamp [11] and was calculated by the product of fasting glucose (mg/dL) and insulin (mmol/L) divided by 405 [12] . Secondary end points included fasting glucose, insulin, glycated hemoglobin, change in body mass index (BMI) and glucose exposure [amount of glucose (grams) prescribed in 24 h]. The primary and secondary outcomes were measured at baseline, 45 and 90 days after the baseline visit. Consults were performed every 2 weeks from baseline to 3 months in order to identify and treat any potential adverse effect related to the study. Insulin was measured by chemiluminescence, glucose by enzymatic method and glycated hemoglobin by high-performance liquid chromatography.
Statistical analysis
Results were expressed as frequencies ( percentages) for categorical variables, mean ± standard deviation (SD) for continuous normally distributed variables and median (interquartile range) for continuous non-normally distributed variables. Normality was checked using Shapiro-Wilk test. Differences between groups on baseline characteristics were analyzed by χ 2 test for categorical data, t-test for continuous normally distributed data and Mann-Whitney U-test for continuous non-normally distributed data. For the primary and secondary outcomes, we compared groups using analysis of covariance (ANCOVA) using the baseline values as covariate, groups as the fixed factor and the value obtained at 90 days as the dependent variable. This statistical approach (ANCOVA) measures the change from baseline excluding the possibility of deriving any result by regression to the mean. In addition, mean changes of the HOMA index from baseline to 45 and 90 days were summarized for each treatment group, and comparative studies were performed using repeated-measures ANOVA. Significance level for alpha was set at <0.05.
R E S U LT S
Patient characteristics at baseline From October 2009 to February 2013, 60 patients were randomly assigned to the intervention (n = 33) or the control (n = 27) group. Thirty-four patients completed 3 months of follow-up, of which 17 were of the control and 17 were of the study group. Details about the cause of dropout in each group can be found in Figure 1 . Two patients, one in each group, were excluded from all analyses because they left the study after randomization but before collection of any blood sample.
Patient characteristics, including glucose metabolism parameters at baseline, are shown in Table 1 . There was no imbalance in any covariate between groups. At baseline, the mean age of the study population was 51.9 ± 16.3 years, hypertension was the main cause of renal disease (35.0%) followed by chronic glomerulonephritis (31.7%), females were 55%, BMI 25.6 ± 4.3 kg/m 2 , glucose exposure 258 ± 59 g/day, daily UF 704 ± 468 mL, residual diuresis 519 ± 554 mL and 13.3% were high transporters. Table 2 summarizes the main results of the study, including primary and secondary outcomes at 90 days.
Primary outcome: changes in HOMA index
The intention-to-treat analysis included 58 of the initial 60 patients. Two patients were excluded because they left the study after signing the term but before the collection of any blood sample. One of them was transplanted, and the other hospitalized with a severe infection complication. Of the 58 patients, there were 27 in the control group and 31 in the icodextrin group. All assumptions for ANCOVA were checked and met. After adjustment for pre-intervention HOMA index levels, there was a statistically significant difference in post-intervention HOMA index between the groups, F = 4.643, P = 0.036, partial η 2 = 0.078. The group treated with icodextrin had the lower post-intervention levels with 1.49 (95% CI: 1.23-1.74) versus 1.89 (95% CI: 1.62-2.17) (Figure 2 ).
O R I G I N A L A R T I C L E
I c o d e x t r i n a n d i n s u l i n r e s i s t a n c e i n A P D
Secondary outcomes
Oral fasting glucose levels were also similar between groups after adjustment for pre-intervention glucose serum levels in the ITT analysis (F = 0.167, P = 0.68, partial η 2 = 0.003). Glucose levels at 3 months were 94.5 mg/dL (95% CI: 88.7-100.2 mg/dL) in the control group and 92.8 mg/dL (95% CI: 87.5-98.2 mg/dL) in the icodextrin group.
There was no need to log-transform insulin for fulfilling the assumptions for the ANCOVA analysis. Adjusted serum insulin for pre-intervention levels was significantly greater in the control group [7. Adjusted serum levels for pre-intervention levels of control and icodextrin groups at 3 months were 4.71% (95% CI: 4.53-4.88%) and 4.83% (95% CI: 4.67-4.99%), respectively.
Ultrafiltration was greater in the icodextrin group both after the long dwell and in 24 h. After adjustments for pre-intervention levels, the UF after the long dwell was 320 mL (95% CI: 186-453 mL) in the icodextrin group and −80 mL (95% CI: −226 to 66 mL) in the control group (F = 16.152, P < 0.001, partial η 2 = 0.237). Regarding total UF, values were 800 mL (95% CI: 669-932 mL) in the icodextrin group and 586 mL (95% CI: 442-731 mL) in the control group (F = 4.833, P = 0.03, η 2 = 0.085).
Safety analysis
Adverse events were continuously reported during the study period by the sub-investigators and their study team. There were a total of 25 adverse events reported, 10 in the control group and 15 in the intervention group. Six events were considered a severe event, 4 in the control group and 2 in the intervention group. There was one death, in the control group, caused by CVD (Table 3) .
D I S C U S S I O N
Glucose exposure during PD is associated with hyperglycemia, new onset diabetes and a status of insulin resistance in observational studies, including patients without diabetes in published observational studies [3, 13] . This is the first multicenter, randomized and controlled study, evaluating the impact of icodextrin in reducing insulin resistance in a group of non-diabetic patients on APD.
It is thought that a good glycemic control in patients with and without diabetes consistently improves outcomes in PD [12, 14, 15] . In a study performed on a contemporary cohort of 2798 diabetic PD patients, poor glycemic control, assessed by HbA1c levels, was associated with lower survival rates [14] . Similar findings were observed in non-diabetic patients: higher oral fasting glucose and HbA1c were associated with high mortality rates after adjustments for covariates respectively in an Asian observational cohort of 405 patients and in 768 patients from the MDRD study [13, 16] . In our study, the substitution of 2 L of glucose-based PD solution for icodextrin on the long dwell did not cause significant change in HbA1c levels. This finding is in line with a previous non-controlled prospective trial with 51 Japanese patients where CAPD patients with HbA1c levels of <6.5% did not show any reduction of HbA1c even after 1 year following the introduction of icodextrin [17] . However, the association between other markers of carbohydrate metabolism, such as insulin resistance, with clinical outcomes is more controversial. A Spanish study of incident (n = 35) and prevalent (n = 34) non-diabetic patients analyzed 69 non-diabetic patients followed up during 1 year did not find any association with mortality and CVD [18] . In contrast, a Chinese prospective cohort study with 66 non-diabetic patients followed for up to 58 months found HOMA-IR as an independent predictor of CV morbidity and mortality [19] . Baseline HOMA-IR levels in our population were very similar to the ones in both studies.
A practical approach to reduce disturbances of the carbohydrate metabolism in PD patients is the reduction of glucose exposure by prescribing glucose-sparing solutions. The substitution of glucose-based solution for icodextrin during the long dwell has been consistently associated with improvement in markers of glucose and lipid metabolism. In a subset of 12 diabetic patients from a prospective Australian pre-post-test study, a significant mean reduction of 1 g/dL after 3 months of the introduction of icodextrin [20] was shown. Another study analyzed 27 prevalent and non-diabetic CAPD patients of which 12 were treated with icodextrin and found a significant improvement in both insulinemia and HOMA-IR in the icodextrintreated patients [21] . More recently, a randomized clinical trial with 59 high transporter diabetic CAPD patients assessed the impact of icodextrin on several carbohydrate metabolism markers. The substitution of one bag of glucose for icodextrin in the long dwell significantly reduced the insulin need, fasting serum glucose, triglycerides and HbA1c [8] .
Our study is the first RCT to assess and observe a reduction in HOMA-IR after substituting glucose-based PD solutions in the long dwell (daytime) for icodextrin in non-diabetic APD patients, most likely as a consequence of the glucose exposure reduction during the long dwell. APD patients overall are exposed to a large amount of glucose during the night time and its impacts on insulin resistance. Reis da Silva et al., evaluating changes in insulin and glucose serum levels during a PET in non-diabetic CAPD patients, observed positive correlations of glucose serum levels and small solutes transport rate possibly reflecting membrane transport characteristics [22] . In our study, all biological sample collections were made from 1 h and halted to a maximum of 3 h after the patient disconnection from the cycler.
One important question that emerges is whether or not this few hours prior to the sampling could have influenced HOMA index levels. Based on the original glucose concentration curve from the PET [23] , we estimate that the glucose absorption in our control group might have ranged from 10 to 30 g of dextrose, depending on the patient membrane profile and time of sampling. Further studies will be necessary to clarify if the improvement in HOMA index lasts for the whole long-dwell period, and/or if our findings represent a short-term benefit of the calorie absorption profile or if they reflect a true resetting of the insulin resistance levels. It is noteworthy that important covariates, such as the membrane characteristics (directly correlated with the amount of glucose absorbed), BMI, the presence of comorbidities (measured by Charlson Index) and finally the use of drugs (BRA, ACEi, aspirin and beta-blockers), which could have affected insulin resistance levels, were similar between groups at baseline. Insulin levels dropped considerably in the intervention group and reached statistical difference at 90 days (Figures 2 and 3) . Previous studies have shown a small decrease in BMI with the use of icodextrin but, more importantly, an important fat mass gain in patients exposed only to glucose [24] has been observed. However, our follow-up was relatively short and there was no change in weight or BMI within or between groups over the study period. One potential positive impact on the long-term use of icodextrin, and likely related to the very welldocumented improvement in the net UF with this osmotic agent, is the need of less glucose-based solutions during the night exchanges [25] . Nevertheless, we did not observe a reduction in glucose exposure at night in our patients. The most probable reason, based on previous clinical experience, may be related to a particular behavior of our patients regarding daily fluid ingestion and more liberal fluid intake in patients with higher UF. Such behavior may counterbalance the UF improvement obtained with icodextrin during the day.
Finally, the analysis of adverse events showed no differences in terms of the safety profile of icodextrin. However, the short follow-up does not allow for capturing differences in adverse events between groups. This study presents some limitations: the number of patients enrolled and completing the study was less than originally calculated; the short-term characteristics of the study; lack of data regarding body composition and measured residual renal function; the dropout rate was higher than expected and caused by unusual clinical situations in our settings such as high transplantation rates and loss of follow-up; and we cannot exclude that the fasting condition was affected by the presence of glucose-containing dialysate. Nevertheless, the interim analysis (with 60 instead of 120 patients) clearly shows that the extension of recruitment would not have changed the results of the primary points, which was reinforced by an observed post hoc power of 83.6%. Second, HOMA index is not the gold standard for insulin resistance measurement; Third, we calculated HOMA index using only one sample and variations within subjects may not be ruled out. However, our study has the following strengths: it is a randomized, multicenter study with a partially blind design, a novel patient population (non-diabetics) inclusion and end point definition (insulin resistance).
In conclusion, icodextrin during the long dwell for nondiabetic patients in APD improves insulin resistance by HOMA index reducing exposure to glucose PD solutions. Whether the reduction in insulin resistance will affect hard clinical end points such as mortality remains to be addressed in future studies.
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